Signaling

Results of BETonMACE with Kausik Ray, MD, FAHA

Kausik Ray, MD, FAHA explains whether treatment with apabetalone compared to standard of care therapies improves CV outcomes in patients with T2DM and low HDL-C after an acute coronary syndrome (ACS). Dr. Ray is a deputy director of Imperial College London's Clinical Trials Unit. See this study and other late-breaking science presentations on our AHA Science News page.

American Heart Association Professional Members

Enjoy instant benefits!

  • Free Online Access to AHA Scientific Journals
  • Affiliate with our 16 Scientific Councils
  • Discounts on Scientific Conference Registration and Online Courses